Results 241 to 250 of about 99,253,553 (299)

Atherosclerosis: From Pathogenesis to Therapeutic Interventions

MedComm, Volume 7, Issue 11, November 2026.
The diagram outlines the core mechanisms driving atherosclerosis, including endothelial dysfunction, inflammatory responses, phenotypic switching of smooth muscle cells, and the gut–vascular axis. It also presents the corresponding therapeutic approaches now under development, such as gene therapies, immunotherapies, and nanotechnology platforms ...
Enge Zhou, Chenxi Zhan, Yuting Li, Yi Zeng, Renfei Luo, Xin Ouyang, Shixing Liu, Renqiang Yang, Nianlong Yan, Long Jiang   +9 more
wiley   +1 more source

Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies

MedComm, Volume 7, Issue 11, November 2026.
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang, Siwen Wu, Yusi Wang, Die Hu, Li Yang   +4 more
wiley   +1 more source

Curcumin in the Treatment of Various Diseases: Mechanism of Action, Bioavailability, Therapeutic Effects, and Current Clinical Trials

MedComm, Volume 7, Issue 11, November 2026.
Curcumin, a naturally occurring polyphenol, exhibits significant anti‐inflammatory and antioxidant capabilities. This review elucidates the specific molecular mechanisms by which curcumin exerts therapeutic effects on various diseases, including neurological disorders, cardiovascular diseases, cancers, inflammatory disorders, and autoimmune diseases ...
Lin Wang, Qifei Pan, Wenjuan Long, Xinyao Li, Jianqin Mao, Sitong Zhou, Zihui Wang, Xuelian Zou, Yuqing She, Mingqin Shi, Yang Zhou, Jiarong Du, Zhongyang Hu, Xiaoman Lv, Yishu Chen, Dongdong Qin   +15 more
wiley   +1 more source

Target Trial Emulation or Target Trial Approximation?

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 11, November 2026.
ABSTRACT Target trial emulation has contributed to improvements in the design and interpretation of observational studies aimed at causal inference. By encouraging researchers to think explicitly about the design of a hypothetical randomized trial, it has helped identify and address avoidable design flaws.
Priya Vart
wiley   +1 more source

Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19

, 2020
Rhee SY, Lee J, Nam H, Kyoung D, Kim DJ.
europepmc   +1 more source

SGLT2 Inhibitor Plus DPP-4 Inhibitor as Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-Analysis

Diabetes, Obesity and Metabolism, 2018
To assess the efficacy and safety of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors plus a dipeptidyl peptidase‐4 (DPP‐4) inhibitor in patients with type 2 diabetes mellitus (T2DM), we performed a systematic review and meta‐analysis of 14 randomized ...
Tiansheng Wang, Dandan Li, Huilin Tang
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Pharmacoeconomic analysis of DPP-4 inhibitors

Die Pharmazie, 2013
Dipeptidyl peptidase-4 (DPP-4) inhibitors and other incretin-related drugs have attracted attention as antidiabetic agents, but they are expensive. The Japanese government has adopted a policy of reducing healthcare costs, and medical institutions must provide medical care while considering economic efficiency.
H, Teramachi, H, Ohta, T, Tachi, M, Toyoshima, T, Mizui, C, Goto, T, Tsuchiya   +6 more
openaire   +3 more sources

The Research Progress of DPP-4 Inhibitors

Mini-Reviews in Medicinal Chemistry, 2020
Diabetes mellitus (DM) is a metabolic disease, and diabetes patients have long-term higher blood sugar levels than standard. Most people with diabetes have complications that greatly affect their standard of living. Patients with type 2 DM occupy the vast majority of all diabetes patients.
Zhi-Gang, Sun, Zhi-Na, Li, Hai-Liang, Zhu   +2 more
openaire   +2 more sources

Efficacy and Cardiovascular Safety of DPP-4 Inhibitors

Current Drug Safety, 2021
Abstract:: Dipeptidyl peptidase-4 (DPP-4) inhibitors or gliptins belong to the class of incretin mimetics. These drugs have been available on the market for the management of type 2 diabetes mellitus (T2DM) for over a decade. Sitagliptin, linagliptin, vildagliptin, saxagliptin and alogliptin are widely available globally, whilst anagliptin ...
Nikhila A. Subrahmanyan, Rithika M. Koshy, Koshy Jacob, Joseph M. Pappachan   +3 more
openaire   +2 more sources

DPP-4 inhibitors: focus on safety

Expert Opinion on Drug Safety, 2014
Dipeptidyl peptidase inhibitors (DPP-4-i) are highly selective inhibitors of the enzyme DPP-4. They act by increasing levels of incretin hormones, which have potent effects on insulin and glucagon release, gastric emptying, and satiety. Our goal is to review the safety issues related to DPP-4-i.This review is based upon a PubMed search of the ...
Sri Harsha, Tella, Marc S, Rendell
openaire   +2 more sources